Donate

News Archive

  • World's first cattle vaccine to reduce E. coli O157:H7 threat receives full licensing approval in Canada
  • More funds for infectious disease research, vaccine development

    The Government of Saskatchewan will increase its annual funding to the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) by $1.7 million.

  • Saskatchewan delegation to attend biotech conference

    Saskatoon's biotech cluster is putting out some tendrils at an industry conference in San Diego, Calif.

  • VIDO launches $2-million project with India to develop tools for improved food safety

    Vaccine and Infectious Disease Organization is a key partner in a $2-million Canada-India initiative to improve food safety through the application of biotechnology in developing an innovative device for rapidly diagnosing disease in cattle.

  • VIDO team awarded $445,000 from PrioNet Canada for BSE vaccine

    PrioNet Canada announced a total of $8 million in funding for 19 projects focusing on prion diseases such as BSE, or “mad cow” disease. Dr. Andrew Potter, VIDO/InterVac director, leads one of two teams based at the U of S that received funding.

  • VIDO scientist receives $620,000 to tackle respiratory disease

    Dr. Sylvia van den Hurk, senior scientist at VIDO, has received $620,000 from the Canadian Institutes of Health Research (CIHR) to develop a needle-free vaccine for a respiratory virus that infects 65 million young children each year.

  • Pan-Provincial Vaccine Enterprise (PREVENT) announces board members, vaccine targets

    Scientific leaders from three of Canada’s foremost public health vaccine research agencies will gather on the U of S campus to launch the $25.5-million Pan-Provincial Vaccine Enterprise (PREVENT), a new national vaccine commercialization consortium

  • VIDO awarded $2.4 million for vaccine coverage tailored to Saskatchewan's needs

    The Saskatchewan Health Research Foundation (SHRF) has awarded VIDO $2.4 million for the establishment of the Research Alliance for the Prevention of Infectious Disease (RAPID), to be led by VIDO director Dr. Andrew Potter.

  • VIDO scientist receives university teaching excellence award

    VIDO congratulates Dr. Scott Napper, member of VIDO’s Science Management team and Program Manager of Emerging Diseases, on his 2008 Teaching Excellence Award from the University of Saskatchewan Students' Union.

  • VIDO key stakeholder in Centre of Excellence for Commercialization and Research

    The University of Saskatchewan will lead a $25.5-million national Centre of Excellence for Commercialization and Research aimed at fast-tracking vaccine development for diseases of major public health concern.